Biotinylated Human PD-L1 / B7-H1 Protein, Fc,Avitag? (MALS verified)
分子別名（Synonym）
PD-L1, CD274, B7-H1, PDCD1L1, PDCD1LG1
表達區(qū)間及表達系統(tǒng)（Source）
Biotinylated Human PD-L1, Fc,Avitag (PDL-H82F2) is expressed from human 293 cells (HEK293). It contains AA Phe 19 - Arg 238 (Accession # Q9NZQ7-1).
Predicted N-terminus: Phe 19
蛋白結構（Molecular Characterization）
This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag?).
The protein has a calculated MW of 53.6 kDa. The protein migrates as 60-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
標記（Labeling）
Biotinylation of this product is performed using Avitag? technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白標記度（Protein Ratio）
Passed as determined by the HABA assay / binding ELISA.
純度（Purity）
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重構方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景介紹
程序性死亡配體1（PDL1）亦稱為B7-H、B7H1、MGC142294、MGC142296、PD-L1、PDCD1L1及PDCD1LG1，是日益擴大的B7免疫分子家族成員，參與細胞免疫與體液免疫的調控。該蛋白為細胞表面免疫球蛋白超家族蛋白，其胞外區(qū)包含兩個免疫球蛋白樣結構域，并具有短胞質結構域。PDL1廣泛表達于大多數(shù)外周組織及造血細胞中。PDL1與屬于CD28分子家族的受體相互作用，在調節(jié)T細胞活化和耐受過程中既傳遞刺激信號也傳遞抑制信號。PDL1可能通過誘導細胞凋亡和阻滯細胞周期進程來抑制持續(xù)進行的T細胞應答。
關鍵字： PD-L1;PD-L1蛋白;PD-L1重組蛋白;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領域提供關鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學等。